| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 23.05.
| Cytori to Present at the Jefferies 2012 Global Healthcare Conference on June 5 | | 12 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 05/23/12 -- Cytori Therapeutics (NASDAQ: CYTX) will present and provide a corporate update from the Jefferies 2012 Global Healthcare Conference on Tuesday, June 5...
Mehr lesen zu:
Cytori to Present at the Jefferies 2012 Global Healthcare Conference on June 5 | |
| 10.05.
| Stock to Watch: Cytori Therapeutics Up 10.4% | | 11 | SmarTrend |
| 09.05.
| Cytori Provides Business Update; Reports First Quarter Results | | 44 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 05/09/12 -- During the first quarter of 2012, Cytori Therapeutics (NASDAQ: CYTX) advanced its cardiac cell therapy product pipeline, grew the commercial business,...
Mehr lesen zu:
Cytori Provides Business Update; Reports First Quarter Results | |
| 27.04.
| Cytori to Webcast First Quarter Financial Results May 9 | | 35 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 04/27/12 -- Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its first quarter financial results and business update on Wednesday, May 9, 2012 at...
Mehr lesen zu:
Cytori to Webcast First Quarter Financial Results May 9 | |
| 16.04.
| Ruling in Texas Could Provide New Opportunities for Stem Cell Companies / Five Star Equities Provides Stock Research on BioTime and Cytori Therapeutics | | 73 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 04/16/12 -- March has shown to be a troublesome month for stem cell stocks. TickerSpy's Stem Cell Stocks Index (RXSTM) has fallen over 16 percent in the last month...
Mehr lesen zu:
Ruling in Texas Could Provide New Opportunities for Stem Cell Companies / Five Star Equities Provides Stock Research on BioTime and Cytori Therapeutics | |
| 19.03.
| Cytori Breast Reconstruction Cell Therapy Trial Results Published | | 60 | MarketWire |
| ZUG, SWITZERLAND and SAN DIEGO, CA -- (Marketwire) -- 03/19/12 -- Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of RESTORE-2 trial results in the peer-reviewed European Journal...
Mehr lesen zu:
Cytori Breast Reconstruction Cell Therapy Trial Results Published | |
| 16.03.
| Cytori Gets 510(k) Clearance From FDA For Puregraft 850 | | 53 | AFX News |
| WASHINGTON (dpa-AFX) - Cytori (CYTX) said it has received 510(k) clearance
from the U.S. Food and Drug Administration or FDA for the Puregraft 850 System
for body contouring using a patient's...
Mehr lesen zu:
Cytori Gets 510(k) Clearance From FDA For Puregraft 850 | |
| 16.03.
| Cytori (CYTX) Receives 510(k) Clearance for Puregraft(R) from FDA | | 3 | StreetInsider.com |
| 16.03.
| FDA Grants Cytori 510(k) Clearance for Puregraft(R) 850 | | 23 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 03/16/12 -- Cytori (NASDAQ: CYTX) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Puregraft® 850 System for body contouring...
Mehr lesen zu:
FDA Grants Cytori 510(k) Clearance for Puregraft(R) 850 | |
| 08.03.
| Cytori Provides Strategic Outlook, Near Term Objectives and Reports Year-End 2011 Results | | 42 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 03/08/12 -- In 2011, Cytori Therapeutics (NASDAQ: CYTX) achieved important objectives towards validating Celution® technology in multiple large market indications...
Mehr lesen zu:
Cytori Provides Strategic Outlook, Near Term Objectives and Reports Year-End 2011 Results | |
| 28.02.
| XETR FFM:New Instruments available on XETRA - 29.02.2012-001 | | 482 | Xetra Newsboard |
| The following instruments on XETRA do have their first trading day 29.02.2012 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 29.02.2012 TrdMod InstCode Exch ISIN Name InstGrp...
Mehr lesen zu:
XETR FFM:New Instruments available on XETRA - 29.02.2012-001 | |
| 23.02.
| Cytori to Webcast Year End Financial Results March 8 | | 23 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 02/23/12 -- Cytori Therapeutics (NASDAQ: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Thursday, March...
Mehr lesen zu:
Cytori to Webcast Year End Financial Results March 8 | |
| 15.02.
| Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing / The Paragon Report Provides Equity Research on Cytori Therapeutics & Cord Blood America | | 108 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 02/15/12 -- Stem cell stocks have performed well of late, outperforming the S&P 500 by a large margin over the last three months. Since mid-November, TickerSpy's Stem...
Mehr lesen zu:
Stem Cell Stocks Skyrocket in 2012 -- Cytori Therapeutics and Cord Blood America on the Upswing / The Paragon Report Provides Equity Research on Cytori Therapeutics & Cord Blood America | |
| 30.01.
| Cytori Therapeutics Receives Investigational Device Exemption Approval From FDA | | 87 | AFX News |
| WASHINGTON (dpa-AFX) - Medical products and devices company Cytori
Therapeutics Inc. (CYTX) said Monday that it received an Investigational Device
Exemption or IDE approval from the U.S....
Mehr lesen zu:
Cytori Therapeutics Receives Investigational Device Exemption Approval From FDA | |
| 30.01.
| Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA | | 29 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 01/30/12 -- Cytori Therapeutics (NASDAQ: CYTX) has received an Investigational Device Exemption (IDE) approval from the U.S. FDA to begin the ATHENA trial. ATHENA...
Mehr lesen zu:
Cytori Receives Approval From FDA to Initiate U.S. Cardiac Cell Therapy Trial; Investigational Device Exemption (IDE) Approved for ATHENA | |
| 24.01.
| Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori's APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function | | 66 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 01/24/12 -- Cytori Therapeutics (NASDAQ: CYTX) announced today the publication of previously reported six-month outcomes from APOLLO, the Company's European clinical...
Mehr lesen zu:
Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori's APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function | |
| 09.01.
| Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to Gain Ground in 2012 / The Paragon Report Provides Equity Research on Aastrom Biosciences & Cytori Therapeutics | | 118 | MarketWire |
| NEW YORK, NY -- (Marketwire) -- 01/09/12 -- Stem Cell stocks -- particularly companies focused on adult stems cells -- have performed well of late. Earlier this month Goldman Sachs noted the potential...
Mehr lesen zu:
Stem Cell Therapy From Aastrom Biosciences and Cytori Therapeutics Looks to Gain Ground in 2012 / The Paragon Report Provides Equity Research on Aastrom Biosciences & Cytori Therapeutics | |
| 05.01.
| The Alliance for Regenerative Medicine Announces Agenda for Regenerative Medicine Insight Track at Biotech Showcase on January 10 and 11 in San Francisco / Speakers Include Advanced Cell Technology, Athersys, Cytori, Dendreon, Genzyme-Sanofi, Johnson &am | | 349 | MarketWire |
| WASHINGTON, DC -- (Marketwire) -- 01/05/12 -- The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine (RM) community, today...
Mehr lesen zu:
The Alliance for Regenerative Medicine Announces Agenda for Regenerative Medicine Insight Track at Biotech Showcase on January 10 and 11 in San Francisco / Speakers Include Advanced Cell Technology, Athersys, Cytori, Dendreon, Genzyme-Sanofi, Johnson &am | |
| 05.01.
| Cytori Announces Presentations at Biotech Showcase on Jan 9th and 10th | | 15 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 01/05/12 -- Cytori Therapeutics, Inc. (NASDAQ: CYTX) will webcast their corporate presentation at the Biotech Showcase at 4:00 PM PT on Monday, January 9 in San Francisco....
Mehr lesen zu:
Cytori Announces Presentations at Biotech Showcase on Jan 9th and 10th | |
| 19.12.
| Cytori Completes IDE Filing for Chronic Myocardial Ischemia ATHENA Trial of the Celution(R) System | | 59 | MarketWire |
| SAN DIEGO, CA -- (Marketwire) -- 12/19/11 -- Cytori Therapeutics (NASDAQ: CYTX) filed its Investigational Device Exemption (IDE) application to begin a clinical trial of the Company's Celution® System...
Mehr lesen zu:
Cytori Completes IDE Filing for Chronic Myocardial Ischemia ATHENA Trial of the Celution(R) System | |
